Darbepoetin's Impact on Preterm Infant Outcomes

This lecture explores the impact of darbepoetin on neurodevelopment and transfusion outcomes in preterm infants. Conducted as a multicenter, randomized, placebo-controlled study involving 650 infants born at 23 0/7 to 28 6/7 weeks of gestation, the research compares weekly administration of darbepoetin to placebo. While no significant cognitive benefits were observed, the darbepoetin group demonstrated fewer transfusions, reduced donor exposures, and lower bronchopulmonary dysplasia (BPD)...